Oncolytics Biotech (TSE:ONC) Trading Up 2.9% – Still a Buy?

Oncolytics Biotech Inc. (TSE:ONC) was up 2.9% on Thursday . The company traded as high as C$1.08 and last traded at C$1.05. Approximately 258,089 shares traded hands during mid-day trading, an increase of 79% from the average daily volume of 144,119 shares. The stock had previously closed at C$1.02.

Wall Street Analyst Weigh In

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The company’s 50 day moving average price is C$1.22 and its 200-day moving average price is C$1.36. The company has a market cap of C$83.78 million, a PE ratio of -2.87 and a beta of 1.35.

Oncolytics Biotech (TSE:ONC) last issued its earnings results on Tuesday, November 12th. The company reported C($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.11) by C($0.01). During the same quarter in the previous year, the company posted ($0.14) earnings per share. Equities research analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.